Data obtained in humans have revealed alterations in chemerin levels in different states such as inflammatory diseases (psoriasis, arthritis, inflammatory bowel disease) or in patients with obesity, type 2 diabetes, and/or metabolic syndrome compared with lean and healthy subjects [20,30,40,41], hence, the relevance of gaining further insight on our understanding of the mechanisms regulating adipose tissue levels of both the ligand and the receptor in relation to food intake and adiposity. Here, RARRES2 is linked to metabolic syndrome.